On Jul 20, 2021 Eyenuk, Inc. received $6,200,000 financing from AXA Investment Managers and Global Health Investment Fund (GHIF). The company plans to close a larger round of financing in late 2021 to support its long-term growth and innovation strategies.
About the company: Eyenuk, Inc. is located in Los Angeles, United States, North America. “Eyenuk, Inc., is a global artificial intelligence (AI) medical technology company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance.” Eyenuk will use the proceeds to immediately accelerate the commercialization of the EyeArt® AI System, which received FDA clearance in 2020 and is being reimbursed by Medicare and other payors.
Company website: www.eyenuk.com